argenx SE

Good morning. My name is Gavin. I'll be your conference operator today. I would like to welcome everyone to the call. At this time, all lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. Thank you.

I'd like to introduce Beth Del Draco, Vice President of Corporate Affairs. You may now begin your call. Thank you.

A press release was issued earlier today with our first quarter of 2026 financial results and business update. This can be found on our website along with the presentation for today's webcast. Before we begin on slide two, I'd like to remind you that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical development, regulatory timelines, the potential success of our product candidates, financial projections, and upcoming milestones. Actual results may differ materially from those indicated by these statements. Our GenX is not under any obligation to update statements regarding the future or to conform those statements in relation to actual results unless required by law. I'm very excited to be joined on the call today by Karen Massey, our new Chief Executive Officer. Today is her first official day on the job, marking a very important milestone in the story of GenX. We're also joined by Carl Bubis, Chief Financial Officer, and Sandrine Perre-Girard, Chief Commercialization Officer. I will now send the call over to Kim. Thanks, Beth, and welcome, everyone.